A positive regulatory environment, combined with a raft of drug approvals that included the first US gene therapy, buoyed the sector in 2017. The FDA's flexibility and focus on marketplace competition is likely to galvanize innovators in the coming year. Chris Morrison reports.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Rapid characterization of secreted recombinant proteins by native mass spectrometry
Communications Biology Open Access 03 December 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2017. Nat Biotechnol 36, 131–136 (2018). https://doi.org/10.1038/nbt.4068
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4068
This article is cited by
-
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products
Pharmaceutical Research (2021)
-
Public biotech in 2017—the numbers
Nature Biotechnology (2018)
-
Rapid characterization of secreted recombinant proteins by native mass spectrometry
Communications Biology (2018)
-
In situ polymerization on biomacromolecules for nanomedicines
Nano Research (2018)